All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition
During the EHA2021 Virtual Congress, the Lymphoma Hub spoke with Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US. We asked, Which factors help guide therapy choice for relapsed/refractory (R/R) diffuse large B-cell lymphoma?
Which factors help guide therapy choice for R/R diffuse large B-cell lymphoma?
In this video, Salles discusses insights presented during EHA2021 regarding the selection of patients with R/R diffuse large B-cell lymphoma for second-line therapy. Although autologous hematopoietic stem cell transplant (auto-HSCT) remains the standard of care, a recent randomized study is comparing auto-HSCT with chimeric antigen receptor (CAR) T-cell therapy. Salles also points out that the antibody-drug conjugate loncastuximab tesirine could be a feasible approach prior to treatment with CAR T-cell therapy.
Gilles Salles | ASH 2018 | MOR208 combined with lenalidomide in patients with R/R DLBCL
Gilles Salles discusses MOR208 combined with lenalidomide in patients with R/R DLBCL at ASH 2018
Satellite Symposium | Sequencing treatment options in primary refractory DLBCL
The virtual Lymphoma Hub Satellite Symposium, at the 16th International Conference on Malignant Lymphoma (16-ICML), saw a panel of international experts come together to...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox